4MODIFIER LETTER PRIME-piperazinacetophenone;
chalcone;
in silico;
HeLa cell line;
PC3 cell line;
anticancer activity;
BIOLOGICAL EVALUATION;
MOLECULAR DOCKING;
ANGELICA-KEISKEI;
DERIVATIVES;
CIPROFLOXACIN;
INHIBITORS;
DESIGN;
ISOLIQUIRITIGENIN;
IDENTIFICATION;
PROLIFERATION;
D O I:
10.1134/S1068162023050096
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
A new series of (E)-3-(substituted phenyl-1-(4-(piperazin-1-yl)phenyl)prop-2-en-1-one derivatives (I-XII) aiming to develop effective anticancer agents were synthesized. The anticancer activities of compound (I-XII) at 100, 50, 25 and 5 & mu;M concentrations were investigated against HeLa (Human cervical cancer cells) and PC3 (Human prostate cancer cells) cancer cells by the BrdU ELISA assay. The anticancer activity results were compared with the standard compound 5-fluorouracil (5-FU). All molecules (except compound (II) for HeLa cancer cells and except compound (X) for the PC3 cell line) were found to be more active than 5-FU. Compound (XI) ((E)-1-(4-(piperazin-1-yl)phenyl)-3-(3-(trifluoromethoxy)phenyl)prop-2-en-1-one) showed high activity in both HeLa and PC3 cell lines, making it an ideal molecule candidate for binary interaction. Drug-likeness, pharmacokinetic properties, and physicochemical properties of all compounds (I-XII) were determined using SwissADME program.